BFM
ABOS icon

Boothbay Fund Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Boothbay Fund Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$644K Buy
273,012
+233,427
+590% +$595K 0.01% 1198
2025
Q4 		$83.5K Sell
39,585
-11,457
-22% -$22.7K ﹤0.01% 1766
2025
Q3 		$87.3K Hold
51,042
– – ﹤0.01% 1743
2025
Q2 		$59.2K Hold
51,042
– – ﹤0.01% 1341
2025
Q1 		$56.1K Hold
51,042
– – ﹤0.01% 1275
2024
Q4 		$87.8K Sell
51,042
-666
-1% -$1.6K ﹤0.01% 1305
2024
Q3 		$128K Sell
51,708
-33,750
-39% -$91.6K ﹤0.01% 1430
2024
Q2 		$207K Buy
85,458
+33,750
+65% +$107K ﹤0.01% 1279
2024
Q1 		$209K Sell
51,708
-30,474
-37% -$115K ﹤0.01% 1324
2023
Q4 		$316K Buy
82,182
+20,997
+34% +$62.3K 0.01% 1168
2023
Q3 		$254K Sell
61,185
-65,921
-52% -$407K 0.01% 1331
2023
Q2 		$611K Buy
127,106
+62,580
+97% +$300K 0.01% 1012
2023
Q1 		$262K Buy
64,526
+1,611
+3% +$8.41K 0.01% 1588
2022
Q4 		$340K Buy
62,915
+335
+0.5% +$2.25K 0.01% 1330
2022
Q3 		$628K Buy
62,580
+49,853
+392% +$286K 0.02% 1107
2022
Q2 		$60K Buy
+12,727
New +$47.8K ﹤0.01% 2060

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Boothbay Fund Management's ABOS Position: Q1 2026 in Review

Boothbay Fund Management increased its Acumen Pharmaceuticals (ABOS) stake by 590% in Q1 2026, buying an estimated $595K and bringing the position to 273,012 shares worth $644K. The position accounts for 0.01% of the portfolio, ranked #1198.

Boothbay Fund Management first reported a position in ABOS in Q2 2022 and has held it in 16 quarters since. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Boothbay Fund Management held 273,012 shares of Acumen Pharmaceuticals worth $644K as of Q1 2026.
  • Boothbay Fund Management bought 233,427 Acumen Pharmaceuticals shares in Q1 2026, an estimated $595K.
  • Acumen Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q1 2026, its #1198 holding.
  • Boothbay Fund Management first reported a position in Acumen Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.